Product Description: AMG-529 is a humanized anti-ASGR1 monoclonal antibody that binds to ASGR1 and blocks ligand binding, resulting in dose-induced increases in ALP, a biomarker of ASGR1 inhibition[1].
Applications: Metabolism-sugar/lipid metabolism
Formula: N/A
References: [1]Janiszewski, M.,et al. A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, ASCENDING SINGLE-DOSE, PHASE 1 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF AMG 529, A NOVEL ANTI-ASGR1 MONOCLONAL ANTIBODY, IN HEALTHY SUBJECTS. Journal of the American College of Cardiology, 73(9), 1755.
Molecular Weight: N/A
Research Area: Metabolic Disease
Target: Phosphatase